Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study

V Channaraya, R K Marya, M Somasundaram, Debashish Mitra, K D Tibrewala, BRIGHT investigators, V Channaraya, R K Marya, M Somasundaram, Debashish Mitra, K D Tibrewala, BRIGHT investigators

Abstract

Objectives: This study was aimed to evaluate the efficacy and tolerability of bisoprolol, in Indian patients diagnosed with stage I essential hypertension as first-line drug.

Design: This was an open-label, phase IV, multicentric prospective study.

Settings: 239 outpatient centres across India.

Participants: After ethical approval, patients who were willing to sign informed consent, who are newly diagnosed with JNC VII stage I essential hypertension (systolic blood pressure 140-159 mm Hg or diastolic blood pressure 90-99 mm Hg) and who are prescribed bisoprolol were enrolled in the study. Patients with significant organ disease or complications, women of childbearing age refusing reliable contraceptive method, patients with known contraindications (like symptomatic bradycardia, significant atrioventricular blockade, sick sinus syndrome) and patients with known hypersensitivity reactions to bisoprolol and unwilling patients were excluded. PRIMARY AND SECONDARY OUTCOMES MEASURES: The primary outcome measure was percentage of patients achieving blood pressure (BP) ≤140/90 mm Hg at the end of 12 weeks, while multiple secondary outcome measures were assessed.

Results: Of 2418 patients screened, 2161 patients were recruited (66.64% men, mean age 51.7±9.8 years, smokers 19.19%) and 2131 (96.44%) patients achieved BP control. There was significant reduction in systolic blood pressure (-25.29; SD: 13.22 mm Hg), diastolic blood pressure (-14.14; SD: 7.67 mm Hg) and heart rate (-12/min; SD: 6.15) compared with baseline (all p values <0.05). The median dose of bisoprolol and average period required for the response were 5 mg/day and 33 days, respectively. Bisoprolol was found to be well tolerated in the patients up to 10 mg/day. A total of 1.9% patients showed adverse events, which were mild to moderate in severity without any severe adverse event. None required treatment withdrawal.

Conclusion: Bisoprolol is an effective and safe option to control BP. Thus, it can be used as one of the first-line antihypertensive in Indian patients.

Conflict of interest statement

Competing interests: None.

References

    1. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006;368:679–86
    1. Rodgers A, Lawes C, MacMahon S. Reducing the global burden of blood pressure-related cardiovascular disease. J Hypertens Suppl 2000;18:S3–6
    1. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291–7
    1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746–53
    1. Vikrant S, Tiwari SC. Hypertension – Pathogenesis and Pathophysiology. Indian Acad Clin Med 2001;2:141–61
    1. Gupta R. Meta-analysis of prevalence of hypertension in India. Indian Heart J 1997;49:450
    1. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004;18:73–8
    1. Mohan V, Deepa M, Farooq S, et al. Prevalence, awareness and control of hypertension in Chennai–The Chennai Urban Rural epidemiology study (CURES-52). J Assoc Physicians India 2007;55:326–32
    1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global Burden of Disease Study. Lancet 1997;349:1498–504
    1. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914–21
    1. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993;94:181–7
    1. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739–45
    1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force document. J Hypertens 2009;27:2121–58
    1. Buhler FR, Berglund G, Anderson OK, et al. Double blind comparison of cardioselective beta blockers in bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter study (BIMS). J Cardiovasc Pharmacol 1986;8(Suppl 11):S122–7
    1. Lenfant C, Chobanian AV, Jones DW, et al. Seventh report of the Joint National committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): resetting the hypertension sails. Hypertension 2003;41:1178–9
    1. Tomlinson B, Dalal JJ, Huang J, et al. The role of beta blockers in the management of hypertension: an Asian perspective. Curr Med Res Opin 2011;27:1021–33
    1. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993;307:107–10
    1. Ogilvie RI, Burgess ED, Cusson JR, et al. Report of the Canadian hypertension Society consensus Conference: 3. Pharmacologic treatment of essential hypertension. CMAJ 1993;149:575–84
    1. Arif AF, Kadam GG, Joshi C. Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine. J Indian Med Assoc 2009;107:730–3
    1. Johns TE, Lopez LM. Bisoprolol: is this just another beta-blocker for hypertension or angina? Ann Pharmacother 1995;29:403–14
    1. Haeusler G, Schliep HJ, Schelling P, et al. High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J Cardiovasc Pharmacol 1986;8(Suppl 11):S2–15
    1. Harting J, Becker KH, Bergmann R, et al. Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol. Arzneimittelforschung 1986;36:200–8
    1. Kaumann AJ, Lemoine H. Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency. Naunyn Schmiedebergs Arch Pharmacol 1985;331:27–39
    1. Klockow M, Greiner HE, Haase A, et al. Studies on the receptor profile of bisoprolol. Arzneimittelforschung 1986;36:197–200
    1. Manalan AS, Besch HR, Watanabe AM. Characterization of [3H](+/-)carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung. Circ Res 1981;49:326–36
    1. Schliep HJ, Harting J. Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs. J Cardiovasc Pharmacol 1984;6:1156–60
    1. Schliep HJ, Schulze E, Harting J, et al. Antagonistic effects of bisoprolol on several beta-adrenoceptor-mediated actions in anaesthetized cats. Eur J Pharmacol 1986;123:253–61
    1. Wellstein A, Palm D, Belz GG. Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol 1986;8(Suppl 11):S36–40
    1. Janka HU, Ziegler AG, Disselhoff G, et al. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986;8(Suppl 11):S96–99
    1. Fogari R, Zoppi A, Tettamanti F, et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol 1990;16(Suppl 5):S76–80
    1. Frithz G, Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S134–8
    1. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427.
    1. Badar VA, Hiware SK, Shrivastava MP, et al. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol 2011;43:437–40
    1. Fogari R, Zoppi A, Corradi L, et al. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999;33:534–9
    1. Frithz G, Weiner L. Effects of bisoprolol, dosed once daily, on blood pressure and serum lipids and HDL- cholesterol in patients with mild to moderate hypertension. Eur J Clin Pharmacol 1987;32:77.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다